Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 8 pages
Data source: Published sources
Topics:
Biggest pharmaceutical companies; ICI; Global investments in pharmaceutical research and development; Novartis; Clinical research; Restructuring at AstraZeneca; Balanced scorecard; Over the counter drugs; Health care services; GlaxoSmithKline; Agrochemicals; Speciality drugs; Prescription pharmaceuticals; Oncology; Neuroscience
Share a link:
https://casecent.re/p/66003
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
Formed on 6 April 1999 through the merger of Zeneca Group Plc from the UK, and Astra AB from Sweden, AstraZeneca is engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and health care services. By 2005, it was among the top five pharmaceutical companies in the world with a turnover of US$21.4 billion. This case, while highlighting the rationale behind the formation of AstraZeneca, offers scope to discuss its growth strategy of focusing on the research and development of innovative drugs to fulfill global health care needs.
About
Abstract
Formed on 6 April 1999 through the merger of Zeneca Group Plc from the UK, and Astra AB from Sweden, AstraZeneca is engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and health care services. By 2005, it was among the top five pharmaceutical companies in the world with a turnover of US$21.4 billion. This case, while highlighting the rationale behind the formation of AstraZeneca, offers scope to discuss its growth strategy of focusing on the research and development of innovative drugs to fulfill global health care needs.